You are here

  • Home
  • Archive
  • Volume 14, Issue 6
  • Efficacy and safety of low-dose corticosteroid with azathioprine in the treatment of elderly-onset IgA vasculitis with nephritis

Article Text

Article menu
Download PDFPDF
Case report
Efficacy and safety of low-dose corticosteroid with azathioprine in the treatment of elderly-onset IgA vasculitis with nephritis
  1. Hikaru Sugimoto,
  2. Yasuko Yamaguchi,
  3. Wako Yumura and
  4. Takashi Takei
  1. Department of Nephrology, Tokyo Metropolitan Geriatric Hospital, Itabashi-ku, Japan
  1. Correspondence to Dr Hikaru Sugimoto; sugimoto.hikaru14{at}gmail.com

Abstract

The diagnosis of elderly-onset IgA vasculitis (IgAV) and its prognosis can be difficult to ascertain because of its rarity and the frequent presence of comorbidities. Furthermore, the treatment of elderly-onset IgAV remains controversial. We report a case of IgAV in an 87-year-old patient. Renal involvement was detected early during the IgAV follow-up. He was treated with low-dose corticosteroid and azathioprine, which led to a complete remission without any adverse effects. This suggests that precise intervention with early diagnosis and careful renal follow-up may prevent renal failure and that low-dose steroids with azathioprine can be an effective treatment for elderly-onset IgAV with nephritis.

  • nephrotic syndrome
  • geriatric medicine
  • vasculitis

https://doi.org/10.1136/bcr-2020-241422

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors HS: wrote the manuscript. WY: provided the histopathological image. YY and TT: completed the literature search and found the relevant articles for the discussion.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.